A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas

Ítems similars

• Novel therapies for relapsed/refractory aggressive lymphomas
  per: Cohen, Jonathon B.
  Publicat: (2018)
• Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
  per: Annunziata, Christina M., et al.
  Publicat: (2012)
• Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
  per: Odejide, Oreofe O.
  Publicat: (2020)
• A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
  per: Huangming Hong, et al.
  Publicat: (2025-04-01)
• Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
  per: BLUM, KRISTIE A., et al.
  Publicat: (2009)